Ent-Oseltamivir - Names and Identifiers
Name | Oseltamivir Impurity 17
|
Synonyms | Ent-Oseltamivir Oseltamivir Impurity 17 (3S,4S,5R)-ethyl 4-acetamido (3S,4S,5R)-ethyl 4-acetamido-5-amino Oseltamivir EP Impurity J(Ent-Oseltamivir) Oseltamivir EP Impurity J HCl(Ent-Oseltamivir HCl) Oseltamivir EP Impurity J HCl(Ent-Oseltamivir HCl) ethyl (3S,4S,5R)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate (3S, 4S, 5R) - 5-acetylamino-4-amino-3 - (pentane-3-oxy) cyclohexene-1-ethyl formate ethyl (3S,4S,5R)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate (3S,4S,5R)-4-acetylamino-5-amino-3-(1-ethylpropoxy)cyclohex-1-enecarboxylicacidethylester
|
CAS | 1035895-88-5
|
Ent-Oseltamivir - Physico-chemical Properties
Ent-Oseltamivir - Introduction
Oseltamivir Impurity 17 is a compound related to oseltamivir (oseltamivir), also known as impurity 17 of oseltamivir. Its chemical properties are as follows:
-Chemical formula: C17H26N2O5P
-Molecular weight: 356.38g/mol
-Appearance: White crystalline powder
-melting point: about 135-140 ℃
Oseltamivir Impurity 17 is mainly one of the degradation products of oseltamivir. It is often used as a reference substance or quality control standard substance in pharmaceutical analysis to test the quality or purity of oseltamivir.
The production method of Oseltamivir Impurity 17 is generally obtained by chemical synthesis. The specific synthetic method may vary according to different researchers and pharmaceutical companies.
As for the safety information of Oseltamivir Impurity 17, since this is a compound, it is necessary to refer to the specific safety data sheet and instructions for its safe use. When using or handling Oseltamivir Impurity 17, follow relevant laboratory safety practices and regulations, and take appropriate personal protective measures, such as wearing gloves, goggles, and protective clothing.
It should be noted that as an impurity, the content of Oseltamivir Impurity 17 in oseltamivir drugs should be controlled at a low level as far as possible to ensure drug quality and safety. Therefore, necessary measures should be taken to control the formation and formation of the Oseltamivir Impurity 17 during drug production and use.
Last Update:2024-04-09 22:09:11